SUMMARY. Renal a 2 -adrenoceptor stimulation by epinephrine infusion reverses cyclic adenosine monophosphate-mediated effects of vasopressin on sodium and water excretion. We used this response to determine whether renal nerve stimulation can activate renal a 2 -adrenoceptors in the non-recirculating isolated perfused rat kidney (Krebs-Henseleit solution; 3.5 g/100 ml Ficoll; 1 g/100 ml albumin; 36°C; propranolol 100 run). In the presence of ai-adrenoceptor blockade with prazosin (30 ITM) <* 2 -adrenoceptor stimulation with epinephrine reversed the cyclic adenosine monophosphate-mediated effects of vasopressin on sodium (P < 0.05) and water (P < 0.05) excretion. Subthreshold (for vasoconstriction) renal nerve stimulation (10 V; 1 msec; 0.65 ± 0.10 Hz) failed to alter the effect of vasopressin. Similarly, higher levels of renal nerve stimulation [plus prazosin (100 nM) or phenoxybenzamine (1.0 mg/kg per hr) to block ai-adrenoceptors] did not activate renal a 2 -adrenoceptors which are associated with the antagonism of the effects of vasopressin. The same level of subthreshold renal nerve stimulation (0.85 ±0.14 Hz) in the absence of vasopressin, and without ai-or a 2 -adrenoceptor blockade, decreased (P < 0.05) sodium and water excretion. The reversal of this effect by ai-adrenoceptor blockade (prazosin 30 nM) but not a 2 -adrenoceptor blockade (yohimbine 300 ITM) indicates that this effect of renal nerve stimulation is mediated through ai-adrenoceptors. Thus, subthreshold renal nerve stimulation in the rat kidney induces sodium and water retention through activation of ai-adrenoceptors, as shown by others in the rabbit and dog. This and even higher levels of renal nerve stimulation failed to activate a 2 -adrenoceptors associated with antagonism of vasopressin. These results are consistent with the theory that ai-adrenoceptors-which mediate sodium and water retentionare located postjunctionally, and that a 2 -adrenoceptors-which antagonize the renal actions of vasopressin-are located extrajunctionally. (Circ Res 57: 304-311,1985) RENAL sympathetic nerves play a tonal role in sodium retention (for reviews, see Kim et al., 1980; DiBona, 1982) . This was initially shown as enhanced water and sodium excretion following renal denervation (Kris et al., 1948; Kaplan and Rapoport, 1951) . Recent studies in conscious rats have confirmed these findings (Rogenes and Gottschalk, 1982; DiBona and Sawin, 1983) . Also, subpressor threshold concentrations of catecholamines (Kim et al., 1980) or renal nerve stimulation (RNS) (Slick et al., 1975; DiBona and Sawin, 1982; Osbom et al., 1983) increase sodium retention. The effects of renal sympathetic nerve stimulation and catecholamines on sodium and water excretion appear to be mediated through either a\-or a 2 -adrenoceptors. Tubular «i-adrenoceptor activation by subpressor RNS in the dog (Osborn et al., 1983) and rabbit (Hesse and Johns, 1984a) increases sodium and water reabsorption. However, the reported effects of renal a 2 -adrenoceptor activation have been variable. Recently, Hesse and Johns (1985) reported finding that a 2 -adrenoceptor activation had no effect on sodium and water excretion. However, other investigations, including that of Hesse and Johns (1985) , have reported an increase in sodium and water excretion. In these studies, infusion of a 2 -adrenoceptor agonists in the dog (Strandhoy et al., 1982 (Strandhoy et al., , 1983 and rabbit (Hesse and Johns, 1985) in vivo, in isolated rabbit cortical collecting-duct segments (Krothapalli et al., 1984) , and in the isolated perfused rat kidney (Smyth et al., 1984a) , increased sodium and/or water excretion. These observed effects of a 2 -adrenoceptor activation were subsequently attributed to antagonism of vasopressin by inhibition of adenylate cyclase in a few of the studies (Krothapalli et al., 1983 (Krothapalli et al., , 1984 Smyth et al., 1985) . Conversely, in the isolated perfused rat kidney in the presence of furosemide, a 2 -adrenoceptor activation decreased the elevated sodium, water, and cyclic adenosine monophosphate (cAMP) excretion (Smyth et al., 1984b) . In these studies, it appears that the effects of a 2 -adrenoceptor stimulation were through reversal of the specific effects of furosemide or vasopressin that were mediated by cAMP. These studies suggested that vasopressin and furosemide stimulated specific adenylate cyclases, whereas epinephrine, through a 2 -adrenoceptors, was a nonspecific inhibitor of these stimulated adenylate cyclases.
The above observations suggest a possible exclu-sivity of ai-adrenoceptor mediation of.sympathetic nerve-stimulated sodium retention and a 2 -adrenoceptor-mediated reversal of endocrine effects. To investigate such a model further, we attempted to determine whether RNS can activate renal a2-adrenoceptors. The a 2 -adrenoceptor effect studied was the reversal of vasopressin-induced sodium and water retention (Strandhoy et al., 1983; Smyth et al., 1984a) . We also investigated whether RNS, in the absence of vasopressin, altered sodium and/or water excretion through activation of ai-or a2-adrenoceptors. The non-recirculating isolated perfused rat kidney was chosen, since a number of extrarenal factors which may alter sodium or water excretion could be eliminated. In addition, we have previously described the reversal of vasopressin's effects by a 2 -adrenoceptor stimulation in this preparation (Smyth et al., 1984a) . The present study confirms that, in the rat, renal nerve stimulation decreases sodium excretion by ai-adrenoceptor activation. The a 2 -adrenoceptor antagonism of vasopressin antisaliuresis could not be induced by subor suprathreshold renal nerve stimulation. These findings are consistent with the hypothesis that etiadrenoceptors are located postjunctionally and mediate sympathetic nerve effects, and that a2-adrenoceptors are extrajunctional in location and mediate the reversal of cAMP-dependent hormonal effects in the kidney.
Methods
Experimental Preparation Male Sprague-Dawley rats (Harlan, Houston; 280-310 g) were anesthetized with pentobarbital (50 mg/kg, ip) and allowed to breathe spontaneously. The right kidney was perfused with a non-recirculating perfusate by a method previously described by Ross et al., (1973) and modified by Smyth et al. (1984a) . The aorta was exposed, afteT an abdominal cruciate incision, by reflecting the abdominal viscera to the right. A loose tie was placed around the right renal artery, and the right ureter was cannulated with polyethylene tubing (PE 50). The superior mesenteric artery was cannulated in the retrograde direction, and the tip of the glass cannula was advanced to the aorta. Perfusate flow was started and the cannula advanced into the right renal artery. The appropriate ligatures were secured. The kidney was removed from the surrounding viscera and placed in a perfusion chamber. The perfusate flow was initially adjusted during the stabilization period to produce a perfusion pressure of 100 mm Hg. Perfusion pressure was measured with an ITT Cannon pressure transducer (Narco Biosystems) on a physiograph (model DMP-4B) connected just proximal to the perfusion catheter.
The perfusion medium was a modified Krebs-Henseleit solution (in NW: NaCl, 110; KC1, 4.7; CaClj, 2.5; KH 2 PO 4 , 1.2; MgSO 4 , 1.2; NaHCO 3 , 26; dextrose, 11.0; urea, 6; 0-alanine, 10; Na 2 HPO 4 , 1.2). Bovine serum albumin (Pentex-fraction V), 1.0 g/100 ml and Ficoll 70 (Sigma), 3.5 g/100 ml, were added to the perfusate. An amino acid mixture was added, as previously described by Epstein et al. (1982) , which produced amino acid levels similar to those observed in normal rat plasma. A /S-adrenoceptor-305 selective concentration of propranolol (100 IVM) was added to the perfusion medium. Creatinine (50 mg/dl) was added for determination of the glomerular filtration rate (GFR). The solution was oxygenated by passing the perfusate through the hollow core fibers of a C-DAK 135sce artificial kidney (Cordis Dow). Equilibration with 95% O 2 -5% CO 2 was achieved by flowing this gas mixture through the dialysate chamber at a rate of 2 liters/min. The perfusate was prefiltered and filtered again (5.0 HM) just before entering the kidney. The temperature of the perfusate at the level of the kidney was 35-37°C with a pH of 7.30-7.40. A Harvard peristaltic pump (model 1210) was used to maintain a pulsatile flow.
Experimental Protocol
After a stabilization period of 15 minutes, four timed urine collections were obtained in preweighed collection tubes. Urine was collected 15-25, 30-40, 40-50, and 50-60 minutes after the start of perfusion. Urine flow rate was determined gravimetrically, and perfusate flow rate was determined volumetrically for each collection period. Experimental treatments were administered immediately before the second urine collection (30-40 minutes). Thus, the first collection period was used to verify adequate renal function of each individual preparation prior to the administration of the experimental interventions. The two major groups studied are listed below.
Renal Nerve Stimulation and Urinary Electrolyte Excretion
In control studies (no interventions) and those in which the effect of RNS was investigated, the area around the renal artery was cleaned of perirenal tissue once perfusion was begun. Two platinum electrodes were placed in contact with the renal artery as close as possible to the end of the cannulated portion. The renal nerves located in this area were then stimulated (Narco stimulator Sl-10) at 10 V and 1.0 msec at a frequency which was below the threshold level required to induce an increase in perfusion pressure. This was determined by starting at 0.3 Hz and gradually increasing the frequency until a slight change in perfusion pressure was observed. Then the frequency was adjusted just below this level. Kidneys that failed to demonstrate an effect by 3.0 Hz were excluded. Similarly, the threshold level was established again at the end of the experiment. Kidneys that failed to demonstrate a threshold similar to that observed at the beginning of the experiment also were excluded.
The role of ai-and/or o 2 -adrenoceptors in mediating the effects of nerve stimulation on sodium excretion was established in two additional separate groups of rats with prazosin (30 nM) and yohimbine (300 run), respectively. In these experiments, infusion of yohimbine or prazosin at the appropriate rate was started immediately before nerve stimulation and was continued throughout the experiment. In these experiments, the subthreshold level of nerve stimulation was established before the antagonist infusions.
Renal Nerve Stimulation and Vasopressin-induced Changes in Sodium and Water Excretion
In these experiments, we attempted to activate, by RNS, renal a 2 -adrenoceptors associated with the antagonism of the effects of vasopressin (Smyth et al., 1984a) . Propranolol and prazosin were used to block /3-and ai-adrenoceptors, respectively, to ensure that only a 2 -adrenoceptors would be activated. Initially, prazosin (30 nM) was used to block ai-adrenoceptors. In these experiments, following the first urine collection, no intervention (control), vasopressin (10 /iU/ml), or vasopressin and renal nerve stimulation (subpressor as above) was administered. The effect of higheT levels of RNS on the action of vasopressin was studied in the presence of a higher dose of prazosin (100 riM) to prevent elevations in perfusion pressure, since changes in renal hemodynamks (i.e., perfusion pressure) may alter sodium excretion. Recent experiments in our laboratory have demonstrated that this dose of prazosin does not alter the a 2 -adrenoceptor-mediated antagonism of vasopressin by epinephrine infusion in this preparation.
In another series of experiments, an ai-adrenoceptorselective infusion of phenoxybenzamine (Smyth et al., 1984a) was used to block ai-adrenoceptors and allow a higher level of RNS before changes in perfusion pressure were observed, hi these experiments, after the first urine collection, no intervention (control), vasopressin (10 /iU/ ml), vasopressin plus epinephrine (28 IIM) and vasopressin, epinephrine, and RNS were administered to the study groups. In all groups studied, rats received an infusion of phenoxybenzamine (1.0 mg/kg per hr), in vivo, before preparation for perfusion was begun.
Perfusate and urine Na + and K + concentrations were determined with a Beckman Klina flame photometer. Creatinine concentrations were determined by a method described by Yatzidis (1974) .
Drugs used and their sources are as follows: vasopressin Table 1 ). (Sigma), yohimbine (Sigma), prazosin (Pfizer), dZ-propranolol (Sigma), /-epinephrine (Sigma), and phenoxybenzamine (Smith, Kline and French). An analysis of variance was used for statistical evaluation. Homogeneity of the variances of the groups studied was established with Bartlett's test (Zar, 1974) . The level of significance between groups was determined with Newman-Keuls multiple comparison test (Zar, 1974) .
Results

Vascular Dynamics
Perfusion pressure and flow were not altered by renal nerve stimulation, even though the GFR tended to decrease (Fig. 1) . In the presence of yohimbine, this decrease in GFR became significant (P < 0.05) for all collection periods after the control period (30-40, 40-50, and 50-60 minutes) . Similarly, RNS in the presence of prazosin depressed GFR, and this was significant (P < 0.05) during the last collection period.
Renal Nerve Stimulation and Electrolyte Excretion
Electrolyte and water excretion prior to any experimental treatments during the control collection period (15-25 minutes) were similar in all the groups Tx studied (Fig. 2) . In the second collection period (30-40 minutes), immediately following the start of the experimental interventions, RNS significantly (P < 0.05) attenuated the magnitude of the spontaneous time-related increase in urine flow rate and the sodium and potassium excretion observed in the control group. Yohimbine and prazosin had no effect on RNS-mediated effects at this time. In the third collection period (40-50 minutes), the experimental treatments had demonstrated significant effects that generally persisted for the duration of the experiment. This time period is therefore presented in detail as representative of the experimental treatments (Table 1) . Subtheshold RNS decreased (P < 0.05) urinary volume (87.2 ± 4.1 to 57.9 ± 3.9 ^1/min), urinary sodium concentration (51.5 ± 3.9 to 29.1 ± 3.4 mEq/ liter) and excretion (4.50 ± .42 to 1.71 ± 0.23 /iEq/ min), urinary potassium excretion (4.08 ± 0.22 to 3.30 ± 0.24 /lEq/min), and the percent fractional excretion of sodium (4.58 ± 0.41% to 1.91 ± 0.27%). a2-Adrenoceptor blockade with yohimbine (300 I\M) had no effect on RNS, and the differences (P < 0.05) observed between the control and RNS groups were also observed between the control and RNS plus yohimbine groups. ai-Adrenoceptor blockade with prazosin (30 ITM) reversed (P < 0.05) the effects of RNS on urinary volume (57.9 ± 3.9 to 82.5 ± 3.3 fil/min), urinary sodium concentration (29.1 ± 3.4 to 48.2 ± 3.4 mEq/liter), and excretion (1.71 ± 0.23 to 3.98 ± 0.34 /iEq/min), urinary potassium excretion (3.30 ± 0.24 to 4.47 ± 0.16 fiEq/min), and the percent fractional excretion of sodium (1.91 ± 0.27% to 4.69 ± 0.79%). Thus, a,-adrenoceptor blockade with prazosin (30 nM) reversed the effect of RNS back to control levels by the third urine collection period (40-50 minutes).
Renal Nerve Stimulation and VasopressinInduced Changes in Sodium and Water Excretion
The above series of experiments demonstrate that oi-adrenoceptors mediated the attenuation of the time-related increases in sodium excretion following subthreshold renal nerve stimulation. The present experiments were conducted in the presence of /3-and ai-adrenoceptor blockade to ensure that only a 2 -adrenoceptors were activated by epinephrine infusion or neuronally released catecholamines. The data presented were obtained during the third urine collection period (40-50 minutes) in each group of rats. In the first urine collection period for data shown in Figures 3 and 4 , no differences in renal hemodynamics or electrolyte and water excretion were demonstrated (data not shown). Similarly, no changes in perfusion pressure, perfusate flow, or glomerular filtration were observed during the third urine collection period (data not shown), the time during which the data shown in Figures 3 and 4 were collected.
Vasopressin (10 /xU/ml) decreased (P < 0.05) urinary volume (87.2 ± 4 . 1 to 60.7 ± 4.8 /il/min), urinary sodium excretion (4.50 ± 0.42 to 1.88 ± 0.40 /jEq/min), and the percent fractional excretion of sodium (4.58 ± 0.41% to 2.05 ± 0.50%) (Fig. 3) . a 2 -Adrenoceptor stimulation with epinephrine (in the presence of prazosin 30 nM) reversed (P < 0.05) vasopressin's effects on urinary volume (60.7 ± 4.8 to 87.2 ± 7.5 /tl/min), urinary sodium excretion (1.88 ± 0.40 to 5.01 ± 0.61 /iEq/min), and the percent fractional excretion of sodium (2.05 ± 0.50% to 4.38 ± 0.53%). Subthreshold renal nerve stimulation (0.65 ± 0.10 Hz) plus prazosin (30 nM), failed to activate a 2 -adrenoceptors and subsequently alter va- sopressin's effects. Suprathreshold levels of RNS (2.0 ± 0.7 Hz), in the presence of increased levels of prazosin (100 nM) also failed to have a significant effect on vasopressin-mediated sodium and water retention. The higher dose of prazosin (100 ITM) was required to ensure antagonism of ai-adrenoceptors at this higher level of RNS. In phenoxybenzamine-pretreated rats (Fig. 4) , vasopressin (10 /iU/ml) decreased (P < 0.05) sodium (5.14 ± 0.66 vs. 1.81 ± 0.41 ^Eq/min) and water excretion (98.0 ± 7.0 vs. 55.0 ± 6.0 ^1/min). a 2 -Adrenoceptor activation by epinephrine (28 run) infusion reversed (P < 0.05) these effects of vasopressin on sodium (1.81 ± 0.41 vs. 5.10 ± 0.77 fiEq/ min) and water excretion (55.0 ± 6.0 vs. 88.0 ± 6.0 fil/min). In the presence of this noncompetitive blockade of ai-adrenoceptors, an even higher level of RNS (2.8 ± 1.0 Hz) than previously tested failed to alter the effects of vasopressin, indicating a failure to activate a 2 -adrenoceptors.
Discussion
Adrenergic nerves terminate in close proximity to basement membranes of proximal and distal tubules (Barajas and Muller, 1973) , the loop of Henle (Ba- rajas et al., 1981), renal blood vessels (Muller and Barajas, 1972) , juxtaglomerular apparatus, and the afferent and efferent arterioles (Barajas and Muller, 1973) . Alterations in renal adrenergic tone, in the absence of renal hemodynamic changes, alter renal sodium handling (Slick et al., 1975; Osbome et al., 1983) . Thus, renal adrenergic nerves have access to the functional tubular units which regulate sodium homeostasis. Although ai-adrenoceptors have been demonstrated to mediate nerve-stimulated sodium retention (Osborn et al., 1983; Hesse and Johns, 1984) , the relationships between a-i-and a 2 -adrenoceptors are unclear. Besarab et al. (1977) and Bello-Reuss (1980) suggsted that catecholamines or renal adrenergic nerves may regulate electrolyte excretion through activation of /S-adrenoceptors. However, their conclusion was based on studies using a very high concentration of propranolol (10~* M) which has nonspecific membrane-stabilizing effects.
Most of the evidence indicates that the effects of renal nerve stimulation on sodium excretion are mediated by a-adrenoceptors. Renal nerve stimulation, in the absence of changes in renal hemody- a Extrajunctional namics, enhanced sodium reabsorption in the dog (DiBona, 1982) . However, the reversal of this effect by relatively nonspecific adrenoceptor blockade with phenoxybenzamine (Zambraski et al., 1976) , phentolamine (Sadowski and Portalska, 1982) , or guanethidine (Slick et al., 1975) failed to identify the a-adrenoceptor subtype(s) responsible. Recently, Osborn et al. (1983) demonstrated in the dog, and Hesse and Johns (1984a) in the rabbit, that suppressor levels of renal nerve stimulation induced an antinatriuresis through activation of renal ct\-adrenoceptors.
The present study verifies this finding in the rat. ai-Adrenoceptor blockade with prazosin blocked the anrinatriuretic action of subthreshold renal nerve stimulation. This ability of the neurotransmitter released by low levels of renal nerve stimulation to activate at-adrenoceptors would suggest that these adrenoceptors were located posrjunctionally but within the synaptic cleft area, as shown in Figure 5 . In the presence of prazosin, no effects of RNS were observed. The failure to observe an effect of RNS when a 2 -adrenoceptors were unblocked would indicate that, under basal conditions, a 2 -adrenoceptors do not alter sodium, water, and potassium excretion. Alternatively, this may indicate that a 2 -adrenoceptors, at least those associated with sodium and water excretion, were located such that RNSreleased neurotransmitter did not have contact with these receptors. Also, since yohimbine alone, an a 2 -selective blocker, did not alter the effect of RNS, it appears to be entirely an ai-adrenoceptor-mediated effect. We extended this study further by attempting to elucidate whether this same level of RNS mediated a well-documented a 2 -adrenoceptor effect. The a 2 -adrenoceptor response studied was the antagonism of vasopressin-induced sodium and water retention (Strandhoy et al., 1983; Smyth et al., 1984a) . These studies were done in the presence of prazosin to reverse the effect of RNS on ct\ -adrenoceptors back to control and ensure that only a 2 -adrenoceptors were activated. Sub-or suprathreshold levels of RNS failed to alter the response to vasopressin, indicating that these a 2 -adrenoceptors were not activated by the released neurotransmitter.
There may be two reasons for the failure to observe an effect on RNS. First, the area of the nephron activated by vasopressin may not receive sympathetic innervation. Vasopressin activates adenylate cyclase in the ascending thin limb of Henle (Jacobson, 1981) , medullary thick ascending limb of Henle (Culpepper and Andreoli, 1983) , and in the medullary and cortical collecting tubules (Jacobson, 1981; Krothapalli and Suki, 1983, 1984) . This activation of adenylate cyclase has been related to altered chloride absorption in mouse medullary thick ascending limbs of Henle (Culpepper and Andreoli, 1983) and altered water absorption in the rabbit cortical collecting tubule (Krothapalli and Suki, 1983,1984) . However, only the effect of vasopressin on adenylate cyclase and wateT absorption in the cortical collecting tubule has been shown to be attenuated by a 2 -adrenoceptor stimulation (Krothapalli and Suki, 1984) . In accord with these findings, studies in our laboratory have demonstrated that vasopressin-stimulated adenylate cyclase is inhibited by a 2 -adrenoceptor stimulation in medullary and cortical collecting tubules and not in the medullary thick ascending limb of Henle in the rat . These studies would indicate, although not conclusively, that a 2 -adrenoceptor stimulation antagonizes the effect of vasopressin stimulated adenylate cyclase predominantly in the cortical collecting tubule. This section of the kidney, as well as the other sites at which vasopressin activates adenylate cyclase, have demonstrated some sympathetic innervation (Kim et al., 1980; Barajas et al., 1984) . Thus, the failure to activate a 2 -adrenoceptors and antagonize the effects of vasopressin could not be directly related to a lack of sympathetic innervation at vasopressin's sites of action. However, whether the specific cell types with which vasopressin interacts were innervated has not been determined.
Thus, a favorable explanation would be that a 2 -adrenoceptors associated with antagonism of the effects of vasopressin (i.e., adenylate cyclase inhibition) were not activated by the neurotransmitter released following low levels of renal nerve stimulation because of their extrajunctional location (Fig.  5) . In parallel to the present study, Yamaguchi and Kopin (1980) observed that the response (pressor) in pithed rats to infused catecholamines was insensitive to a i-antagonists but was selectively blocked by a 2 -antagonists, whereas the response (pressor) following nerve stimulation was selectively blocked by ai-antagonists. Similar findings have been reported by Willfert et al. (1982) . These and similar findings in other species have led to the hypothesis that (at least in arterial tissue) c^-adrenoceptors are located postjunctionally, and a 2 -adrenoceptors, extrajunctionally Van Zwieten, 1981, 1982; Langer and Shepperson, 1982; Langer and Hicks, 1984; Ruffolo, 1984) . This proposed model in the vasculature of normal rats is consistent with that proposed in the present study (Fig. 5) . The major differences are that the end-organ response in the vasculature is vasoconstriction, and, in this tissue, a 2 -adrenoceptors may be associated with calcium channels rather than the adenylate cyclase system (Timmermans and Van Zwieten, 1982) . Thus, nerve stimulation would physiologically activate postjunctional ai-adrenoceptors. Circulating catecholamines, however, would predominantly activate extrasynaptic a 2 -adrenoceptors with the ct\-adrenoceptor being activated only under pathophysiological conditions when circulating catecholamine levels are high or if their affinity or number should increase.
In the original functional classification of a^-and a 2 -adrenoceptors, Berthelsen and Pettinger (1977) proposed a 'postsynaptic* location for the multitudinous a 2 -adrenoceptors on plasma membranes of effector cells. According to this new evidence, the localization should now be more specifically defined as 'extrajunctional site* of a 2 -adrenoceptors, as in Figure 5 .
In the present study, subpressor levels of renal nerve stimulation and epinephrine infusion (with ai-adrenoceptor blockade) were administered to avoid changes in renal hemodynamics. In a number of nonrenal vascular beds in various species, catecholamines can induce vasoconstriction by activation of ai-and/or a 2 -adrenoceptors (Langer and Hicks, 1984) . However, in the renal vasculature, the ai-adrenoceptor appears to be the predominant reCirculation Research/Vo/. 57, No. I August 1985 ceptor mediating this effect in the dog (Horn et al., 1982) , the cat (Drew and Whiting, 1979) , and the rat (Schmitz et al., 1981; Wolff et al., 1985) . At present, only studies in the rabbit have demonstrated that both a\-and a 2 -adrenoceptors mediated a considerable renovasoconstriction (Hesse and Johns, 1985) . Thus, in the present study, vascular a 2 -adrenoceptors need not be considered in the interpretation of the results.
Finally, a 2 -adrenoceptors have only recently been identified, and, subsequently, their physiological function(s) have yet to be described in detail. Another effect of a 2 -adrenoceptor stimulation not measured in the present study or elucidated at present may be reversed by RNS.
In conclusion, at-and a 2 -adrenoceptor stimulation alters sodium and water excretion. Stimulation of ai-adrenoceptors increased basal sodium and water reabsorption (present study), whereas a 2 -adrenoceptor activation had no effect on basal (i.e., no furosemide or vasopressin) sodium and water excretion (Smyth et al., 1984b Hesse and Johns, 1985) . The effects of renal denervation and renal nerve stimulation on sodium retention previously documented are probably mediated by ai-adrenoceptors located postjunctionally (Osborn et al., 1983; Hesse and Johns, 1984a ; present study). Qualitatively, a 2 -adrenoceptors (extrajunctional) may decrease (Smyth et al., 1984b) , increase (Strandhoy et al., 1983; Smyth et al., 1984a; Hesse and Johns, 1985) , or have no effect (Hesse and Johns, 1985) on sodium excretion. These effects appear to be dependent on the function specificity of the predominant adenylate cyclase-cAMP activated at any given moment (Smyth et al., 1984b) and may be dependent on blood-borne hormones (i.e., epinephrine), rather than on neuronally released catecholamines (i.e., norepinephrine).
